Human Milk Oligosaccharides Market is Likely to Register 12.3% CAGR till 2024
26 November 2018 –
The global Human
Milk Oligosaccharides (HMO) Market size is expected to reach USD 170.4 million by 2024. It is
anticipated to expand at a CAGR of 12.3% over the forecast period. HMO is a
bioactive complex sugar molecule, which promotes growth of healthy bacteria,
such as bifid bacteria genus in human gut. It also and helps improve metabolic
activity in human body. In addition, incorporation of HMO in the formulation of
functional foods and beverages not only promotes growth of healthy bacteria but
also eliminates harmful microbes such as salmonella, listeria, and
campylobacter.
High infant mortality rate coupled with
rising demand for human milk donors in North America is one of the major
drivers for the HMO market. North America accounted for around 25.0% of global
market share in 2015 and is projected to expand further during the forecast
period. Growing demand for infant food especially for infants with
non-lactating mothers coupled with strong presence of infant formula
manufacturers in U.S. is expected to have a positive impact on regional market.
Besides North America, Europe is one of the key markets for human milk
oligosaccharides. Presence of a large biotechnical institutes engaged in the
development of enzyme formulations in Germany, U.K., and France is encouraging
HMO manufacturers to establish tie-ups to improve their R&D activities.
Browse Details of
Report @ https://www.hexaresearch.com/research-report/human-milk-oligosaccharides-hmo-market
Over the past few years, many R&D
institutes have launched chemically synthesizing techniques and cow milk
processing methods for the production of HMO. Extraction of human milk
oligosaccharides is a bit expensive due to the limited access to raw materials.
Product innovations aimed at improving brain health, are expected to pose a
threat to the existing market participants. According to the World Health
Organization (WHO), the world population is expected rise by over a billion in
the next 10 years. This factor is anticipated to propel demand for infant food,
thereby driving the global market.
The HMO is also useful for adults as
it helps maintain health of the digestive system. The ingredient acts as a
microbiota modulator and maintains health of the immune system. HMO also helps
prevent T1D, which interacts between the innate immune system and intestinal
microbes in adults. High demand for digestive health supplements among adults
due to rising concerns regarding gastrointestinal disorders is expected to promote
market growth.
Some of the key manufacturers in the
Human Milk Oligosaccharides (HMO) market include Inbiose; Jennewein
Biotechnologie GmbH; Elicityl SA; Glycom A/S; ZuChem, Inc.; Medolac
Laboratories; and Glycosyn LLC. Increased number of health claims in U.S. and
several developed markets of Europe has spurred studies to explore the
potential of HMO. These studies have derived different microbial challenges in
gut, prevention of diarrhea, and protection from infectious diseases. In
September 2013, ZuChem launched new HMO formulations including l-galactose, as
well as sugar phosphates such as β-l-glucose-1-phosphate,
α-d-galactose-1-phosphate, and β-l-xylose-1-phosphate. In October 2014, U.S.
based Madolac Laboratories completed construction of second phase of HMO
purification plant. This plant will synthesize human milk oligosaccharides on a
large scale, which will be further used in clinical trials and scientific
research.
Hexa Research has segmented the global
human milk oligosaccharides (HMO) market report based on application and
region:-
Segmentation by
Application
• Infant Formula
• Functional Food & Beverages
• Food Supplements
• Others
• Infant Formula
• Functional Food & Beverages
• Food Supplements
• Others
Segmentation by
Region
• North America
• U.S.
• Europe
• U.K.
• Germany
• Asia Pacific
• China
• Japan
• Latin America
• Brazil
• MEA
• North America
• U.S.
• Europe
• U.K.
• Germany
• Asia Pacific
• China
• Japan
• Latin America
• Brazil
• MEA
Key players
analyzed:
• Inbiose NV
• Elicityl S.A.
• Jennewein Biotechnologie GmbH
• Glycom A/S
• Medolac Laboratories
• ZuChem Inc.
• Glycosyn LLC
• Inbiose NV
• Elicityl S.A.
• Jennewein Biotechnologie GmbH
• Glycom A/S
• Medolac Laboratories
• ZuChem Inc.
• Glycosyn LLC
Browse
Related Category Market Reports@ https://www.hexaresearch.com/research-category/nutraceuticals-and-functional-foods-industry
About Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com
Comments
Post a Comment